Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Share-based Compensation (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Share-based Compensation for 16 consecutive years, with $2.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 9.0% to $2.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.1 million, a 23.2% decrease, with the full-year FY2025 number at $10.1 million, down 23.2% from a year prior.
  • Share-based Compensation was $2.5 million for Q4 2025 at Anika Therapeutics, up from -$132000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $6.7 million in Q2 2024 to a low of -$132000.0 in Q3 2025.
  • A 5-year average of $3.2 million and a median of $3.1 million in 2021 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: surged 1191.3% in 2021, then tumbled 113.65% in 2025.
  • Anika Therapeutics' Share-based Compensation stood at $3.2 million in 2021, then decreased by 1.8% to $3.1 million in 2022, then grew by 22.71% to $3.8 million in 2023, then crashed by 40.89% to $2.3 million in 2024, then grew by 9.0% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Share-based Compensation are $2.5 million (Q4 2025), -$132000.0 (Q3 2025), and $4.8 million (Q2 2025).